This page collects WhisperX intelligence signals tagged #Eli Lilly. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
AI drug developer Insilico Medicine has secured a major commercialization deal with pharmaceutical giant Eli Lilly, a pact valued at up to $2.75 billion. The agreement, announced Sunday, grants Lilly the rights to develop, manufacture, and commercialize a portfolio of Insilico's preclinical drug candidates discovered u...
Novo Nordisk's top US executive is publicly addressing the competitive threat from Eli Lilly's newly approved obesity pill, signaling a direct corporate response to a major market shift. In a Bloomberg interview, Executive Vice President for US Operations Jamey Millar discussed the implications of the rival drug's entr...
A dramatic last-minute surge, fueled by two major acquisitions, saved the biotech sector from closing the first quarter in the red. The closely watched SPDR S&P Biotech ETF (XBI) was on track for a quarterly loss until the final trading day, when Eli Lilly's announced purchase of Centessa Pharma and Biogen's takeover d...
The Trump administration's high-profile plan to provide seniors with cheap weight-loss drugs through Medicare is hitting a major roadblock. The initiative, which hinges on a voluntary pilot program, is at risk of unraveling as key health insurers signal deep reluctance to participate, fearing the arrangement will be a ...
Eli Lilly has entered a collaboration with AI-focused biotech Profluent to develop next-generation gene editors capable of inserting entire genes into patients, signaling a major escalation in the pharmaceutical giant's ambitions in genetic medicine. The deal structure includes up to $2.25 billion in milestone payments...